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ABSTRACT: Tumor-associated macrophages (TAMs) are
increasingly considered a viable target for tumor imaging and
therapy. Previously, we reported that innovative surface-
functionalization of nanoparticles may help target them to
TAMs. In this report, using poly(lactic-co-glycolic) acid
(PLGA) nanoparticles incorporated with doxorubicin (DOX)
(DOX-NPs), we studied the effect of surface-modification of
the nanoparticles with mannose and/or acid-sensitive shed-
dable polyethylene glycol (PEG) on the biodistribution of
DOX and the uptake of DOX by TAMs in tumor-bearing
mice. We demonstrated that surface-modification of the DOX-NPs with both mannose and acid-sensitive sheddable PEG
significantly increased the accumulation of DOX in tumors, enhanced the uptake of the DOX by TAMs, but decreased the
distribution of DOX in mononuclear phagocyte system (MPS), such as liver. We also confirmed that the acid-sensitive sheddable
PEGylated, mannose-modified DOX-nanoparticles (DOX-AS-M-NPs) targeted TAMs because depletion of TAMs in tumor-
bearing mice significantly decreased the accumulation of DOX in tumor tissues. Furthermore, in a B16-F10 tumor-bearing mouse
model, we showed that the DOX-AS-M-NPs were significantly more effective than free DOX in controlling tumor growth but
had only minimum effect on the macrophage population in mouse liver and spleen. The AS-M-NPs are promising in targeting
cytotoxic or macrophage-modulating agents into tumors to improve tumor therapy.
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■ INTRODUCTION
Numerous studies have revealed the importance of TAMs on
tumor growth and development.1−4 TAMs are innate immune
effector cells recruited to tumor tissues.5 They are present in
both tumor stroma and nests,6,7 accounting for up to 50% of
tumor mass.8 TAMs contribute to tumor growth by producing
stromal breakdown factors and by suppressing adaptive
immunity.9 Moreover, TAMs induce chemoresistance by
inhibiting tumor cell apoptosis.10 Recently, there is also
compelling evidence that TAM infiltration in tumors is
correlated with poor prognosis of many cancers, including
breast, pancreatic, ovarian, prostate, cervix, bladder cancer, and
certain types of glioma and lymphoma in patients.11−17 TAMs
are thus considered a potentially viable target in designing
innovative imaging and therapy strategies. In fact, there are
various reported methods to target TAMs. Among them, using
the membrane receptors on TAMs is commonly explored.18−21
For example, the endocytic CD163 protein was recently
proposed as a TAM target for anticancer and antiangiogenesis
drug design.22 Folate receptor-β, another protein commonly
expressed on the surface of macrophages, had also been
exploited to target toxins to TAMs.23,24 Because TAMs
overexpress mannose receptor (MR),25 there had been efforts
to increase the delivery of oligos, DNA, imaging agents, and
vaccines to TAMs by surface-modifying the delivery systems
with mannose derivatives,26,27 anti-MR nanobody,28 or
galactose derivative.29 Unfortunately, many of the previously
reported delivery systems can be inevitably taken up by
macrophages that are not in tumors because those macrophages
often express similar membrane receptors as the TAMs do.30
To address this issue, we recently constructed an acid-
sensitive sheddable PEGylated, mannose-modified nanoparticle
platform (AS-M-NPs). The nanoparticles are prepared with
PLGA, surface-modified with mannose, and PEGylated with an
acid-sensitive PEG amphiphile, PEG-hydrazone-C18 (or PHC),
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which was synthesized by conjugating PEG (molecular weight,
2000) with stearic hydrazide using a hydrazone bond.31 It was
theorized that upon intravenous (i.v.) injection, the long
flexible PEG chains shield the mannose on the surface of the
nanoparticles and prevent the interaction of the nanoparticles
with macrophages before the nanoparticles reach tumors. Once
the nanoparticles accumulate in tumors by the enhanced
permeability and retention (EPR) effect,32 however, the slightly
acidic tumor microenvironment (∼ pH 6.84)33 helps catalyze
the hydrolysis of the hydrazone bond and facilitate the
shedding of the PEG chains, exposing the mannose for
interaction with MRs on the surface of TAMs. Previously, we
showed fluorescence images of the histological sections of
tumors in mice injected with fluorescein-labeled AS-M-NPs,
which indicated that the AS-M-NPs can potentially target
TAMs.34 However, direct evidence is needed to demonstrate
that the AS-M-NPs can indeed target TAMs.
In the present report, we present ex vivo fluorescence
imaging data to demonstrate that surface-modification of PLGA
nanoparticles incorporated with the self-fluorescent DOX with
acid-sensitive sheddable PEG and mannose can effectively
target the DOX into tumors by interacting with TAMs.
Moreover, by taking advantage of the cytotoxicity of DOX, we
showed that the DOX-AS-M-NPs were more effective than free
DOX in inhibiting tumor growth. The DOX-AS-M-NPs
significantly decreased TAM population in tumors, but showed
only minimum effect on macrophages in mouse MPS organs
such as liver and spleen.
■ MATERIALS AND METHODS
Materials. O-Stearoyl mannose (M-C18), polyethylene
glycol 2000-hydrazone-C18 (PHC), and polyethylene glycol
2000-amide-C18 (PAC) were synthesized following our
previously published methods.31,34 Doxorubicin hydrochloride
was from Fisher Scientific Co. (Pittsburgh, PA). Zoledronic
acid, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT), PLGA (752H), and poly-D-lysine were from
Sigma-Aldrich (St. Louis, MO). Mannose was from Tokyo
Chemical Industry Co., Ltd. (Portland, OR). Hematoxylin-
eosin (H&E) and anti-CD31 antibody were from Abcam
(Cambridge, MA). Hoechst 33342 was from AnaSpec, Inc.
(Fremont, CA). The 5-bromo-2′-deoxyuridine (BrdU) and
primary BrdU monoclonal antibody were from BD Biosciences
(San Jose, CA). Anti-CD206, RM0029-11H3, and FITC-
labeled anti-CD206 antibody were from Santa Cruz Bio-
technology, Inc. (Dallas, TX). Solvents used in chemical
synthesis were of analytical grade.
Cells and Animals. J774A.1 macrophage cells, B16-F10
murine melanoma cells, BxPC-3 human pancreatic cancer cells,
and TC-1 murine lung cancer cells were from American type
Culture Collection (ATCC, Manassas, VA) and cultured in
DMEM (or RPMI1640 for BxPC-3) at 37 °C and 5% CO2.
Media were supplemented with 10% fetal bovine serum (FBS),
100 U/mL of penicillin, and 100 μg/mL of streptomycin, all
from Invitrogen (Carlsbad, CA). Female C57BL/6 mice (6−8
weeks) and male athymic nude mice were from Charles River
Laboratories (Wilmington, MA). Animal studies were per-
formed in accordance with the National Research Council
guide for the care and use of laboratory animals. Animal
protocol was approved by the Institutional Animal Care and
Use Committee at The University of Texas at Austin.
Preparation and Characterization of Doxorubicin
(DOX)-Loaded Nanoparticles. Nanoparticles were prepared
following our previously reported method with slight
modifications.34 Briefly, 0.9 mL of tetrahydrofuran (THF)
containing PLGA 752H (3 mg) and DOX (0.3 mg) was added
dropwise into 4.5 mL of water under stirring. The nanoparticles
were collected by centrifugation (13 000 × g, 10 min, 4 °C)
after the evaporation of THF. For the purpose of surface
modification, M-C18 (1.2 mg), PAC (1.2 mg), or PHC (3.6
mg) were dissolved together with PLGA and DOX in THF and
added into water.34 Particle sizes and zeta potentials of the
nanoparticles were determined using a Malvern Zeta Sizer
Nano ZS (Westborough, MA). The morphology of the
nanoparticles was analyzed using a Zeiss Supra 40 VP Scanning
Electron Microscope (SEM) (Zeiss SMT AG, Oberkochen,
Germany) in the ICMB Microscopy and Imaging Facility at the
University of Texas at Austin.35 The entrapment efficiency
(EE) of DOX was determined spectrophotometrically at 490
nm by measuring the amount of free unentrapped DOX in the
external aqueous solution after centrifugation of the nano-
particles in suspension for 5 min at 13 000 × g. To determine
the total amount of DOX in the nanoparticles, 500 μL of
nanoparticles in suspension were mixed with 4.5 mL of
dimethyl sulfoxide (DMSO) for 5 min by sonication, and the
concentration of DOX was determined. The EE was calculated












In Vitro Release of DOX from Nanoparticles. The rate at
which DOX was released from nanoparticles was measured as a
function of time when the nanoparticles were incubated in
phosphate-buffered saline (PBS, pH 7.4 or 6.8, 10 mM).
Triplicate samples of 5 mg of nanoparticles were suspended in
0.5 mL of PBS and sonicated briefly in an ultrasonic water bath.
The samples were then incubated in an orbital shaker at 37 °C,
100 rpm. At various time points, the particles were centrifuged
at 13 000 × g for 5 min, and 100 μL of supernatant was
removed and replaced with fresh PBS. The fluorescence
intensity of DOX in the supernatant was measured using a
BioTek Synery HT Multi-Mode Microplate Reader (Winooski,
VT, USA) at excitation 470 nm/emission 590 nm to determine
the DOX released from nanoparticles.
Intracellular Uptake of DOX by J774A.1 Cells. J774A.1
cells were seeded with a density of 5 × 105 cells per well on
poly-D-lysine-precoated glass coverslips, placed inside wells of a
6-well tissue culture plate, and incubated overnight. On the
second day, cell culture medium was replaced with 2.5 mL of
50 μM DOX in various nanoparticles (i.e., DOX-NPs, DOX-M-
NPs, DOX-AI-M-NPs, and DOX-AS-M-NPs). Cells were
incubated for 20 min, followed by five additional minutes of
incubation with 50 μM Hoechst 33342 in a 37 °C incubator
and protected from light. Cells were then washed with PBS
three times, fixed with 4% paraformaldehyde, and observed
under a fluorescence microscope (Olympus BX 53, Center
Valley, PA) connected to the Olympus cellSens Dimension
software. To investigate the effect of pH on the cellular uptake,
nanoparticles were preincubated with PBS (pH 6.8) at 37 °C
for 6 h before further incubating with cells.
In order to track the intracellular fate of nanoparticles, DOX-
AS-M-NPs were prepared with 5% (w/w) of PLGA 752H that
was conjugated with fluorescein isothiocyanate (FITC).34 Cells
were incubated with nanoparticles for 15, 30, or 60 min,
followed by five additional minutes of incubation with Hoechst
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33342. Cells were then washed, fixed, and observed under a
microscope as mentioned above.
In Vitro Cytotoxicity Assay. B16-F10 cells (80%
confluence) were plated at a cell density of 5 × 103 cells/well
into 96-well plates. After 24 h of incubation at 37 °C with 5%
CO2, the growth medium was removed, and the cells were
incubated for another 24 h with various DOX formulations,
with DOX concentrations ranging from 0.001 to 10 μg/mL.
Controls included cells incubated with DOX-free medium or
blank nanoparticles (i.e., DOX-free AS-M-NPs). Cells were
washed twice with PBS and incubated with 20 μL of MTT (5
mg/mL) solution for 4 h. Formazan crystals were solubilized
with 150 μL of DMSO. The absorbance of each well at 570/
630 nm was measured. Cell viability was calculated by
comparing the absorbance with the untreated cells.
To evaluate the cytotoxicity of the DOX-NPs in macro-
phages, J774A.1 cells were seeded into 96-well plates at a cell
density of 1 × 105 cells/well.36 After 24 h of incubation, cells
were treated with free DOX or various DOX-NPs, and cell
viability was determined 24 h later using an MTT assay as
mentioned above. Similarly, controls included cells incubated
with DOX-free medium or DOX-free AS-M-NPs.
Biodistribution Studies. C57BL/6 mice were subcuta-
neously (s.c.) injected with B16-F10 cells (5 × 105/mouse) in
the right flank. When tumors reached around 7 mm in
diameter, mice were i.v. injected with PBS, free DOX solution,
DOX-NPs, DOX-M-NPs, DOX-AI-M-NPs, DOX-AS-NPs, or
DOX-AS-M-NPs (DOX dose, 10 mg/kg). Mice were
euthanized 6 h later to collect blood, tumor, and major organs
(e.g., heart, kidneys, liver, spleen, and lung). All samples were
then imaged using an IVIS Spectrum (Caliper, Hopkinton,
MA) (Em/Ex of 465/600 nm).
In order to evaluate the effect of TAMs on the uptake of the
DOX-AS-M-NPs by tumors in mice, B16-F10 tumor-bearing
C57BL/6 mice were intraperitoneally (i.p.) injected with
zoledronic acid (5 mg/kg) 7 days after tumor cell injection
to reduce macrophages in mice.37 Zoledronic acid injection was
repeated every 4 days for 4 more times. Two days after the last
injection (i.e., 25 days after tumor cells injection), mice were i.v.
injected with DOX-AS-M-NPs (DOX, 10 mg/kg). As controls,
B16-F10 tumor-bearing mice that were not treated with
zoledronic acid were i.v. injected with DOX-AS-M-NPs or
sterile PBS. Mice were euthanized 6 h later to collect tumor and
major organs for ex vivo imaging using IVIS Spectrum. Tumor
tissues were also stained with RM0029-11H3, a macrophage
marker, to confirm the reduction of TAMs by treatment with
zoledronic acid.
Finally, to evaluate the kinetics of the biodistribution of the
DOX-AS-M-NPs in mice, B16-F10 tumor-bearing mice were
i.v. injected with DOX-AS-M-NPs (10 mg DOX/kg), and three
mice were euthanized 6, 12, 24, or 48 h later to collect tumor,
blood, and major organs, which were then imaged using the
IVIS Spectrum.
For mice bearing BxPC-3 and TC-1 tumor, 2 × 106 or 5 ×
105 cells were s.c. inoculated in athymic male nude mice or
C57BL/6 mice, respectively. When tumor grew to around 7
mm in diameter, mice were grouped and i.v. injected with
DOX-AS-M-NPs, free DOX, or sterile PBS. Mice were
euthanized 6 h (BxPC-3 tumor-bearing mice) or 12 h (TC-1
tumor-bearing mice) later to collect tumors and major organs
for ex vivo imaging.
In Vivo Antitumor Activity. C57BL/6 mice were s.c.
injected with B16-F10 cells (5 × 105/mouse) in the right flank
on day 0. On day 6, mice were randomized (n = 8) and i.v.
injected with PBS, free DOX solution, or DOX-AS-M-NPs.
The dose of DOX was 5 mg/kg. Treatment was repeated on
day 12. Tumor size and mouse body weight were monitored
every day. Tumor volume was calculated using the following
equation:38 tumor volume = (length × width2)/2. On day 16,
mice were euthanized to collect tumor, liver, and spleen. Mice
were i.p. injected with BrdU, 100 μg/g body weight, 30 min
prior to euthanasia. Tissue samples were weighed and fixed for
immunohistochemical staining. Tumor tissues were stained
with H&E or anti-CD206, anti-CD31, or anti-BrdU antibodies.
Liver and spleen tissues were sectioned and stained with
RM0029-11H3.
Uptake of AS-M-NPs by Macrophages in B16-F10
Tumors. C57BL/6 mice were s.c. injected with 5 × 105 B16-
Figure 1. Characteristics of DOX-incorporated nanoparticles and their IC50 values. (A) Physical characteristics of various DOX-nanoparticles. (B) A
representative SEM graph of DOX-AS-M-NPs. (C) The in vitro release profile of DOX from DOX-AS-M-NPs (inset, the release profile in the initial
8 h). (D) IC50 values of free DOX and various DOX-nanoparticles in B16-F10 cells and J774A.1 cells. As a control, the cytotoxicity of the DOX-free
AS-M-NPs was also evaluated (*The IC50 values of the DOX-free AS-M-NPs are the equivalent DOX concentrations, if the AS-M-NPs were
incorporated with DOX). Data in panels A, C, and D are mean ± SD (n ≥ 3). In panel D, a−dp < 0.05.
Molecular Pharmaceutics Article
dx.doi.org/10.1021/mp500565q | Mol. Pharmaceutics 2014, 11, 4425−44364427
F10 cells. When tumors reached about 9 mm, mice were
randomized and i.v. injected with PBS, free DOX, or various
DOX-nanoparticles. The dose of DOX was 10 mg/kg. Mice
were euthanized 6 h later to collect tumors. Tumor cell
suspensions were stained with FITC-labeled anti-CD206
antibodies (1:200 dilution) for 20 min on ice and washed 3
times with PBS. Cells were then analyzed using a BD FACS
Aria Flow Cytometer (San Jose, CA). The percent of CD206+
cells that took up DOX (i.e., DOX+/CD206+%) was analyzed
with the Flow Jo software (Tree Star Inc., Ashland, OR). Dead
cells and cells debris were excluded based on the FSC-SSC plot.
Live cells were then plotted in the green (FITC) vs red (DOX)
dot plot quadrants. Double negative control was the tumor
tissue single cell suspension from mice that were injected with
sterile PBS. Positive control was the FITC-anti-CD206 stained
tumor tissue single cells isolated from mice that were injected
with sterile PBS. Positive control for the DOX was the tumor
tissue single cell suspension from mice that were injected with
sterile PBS, and the cells were coincubated with a DOX
solution in culture for 20 min.
Statistics. Statistical analyses were completed by performing
ANOVA followed by Fisher’s protected least significant
difference procedure. A P value of ≤0.05 (two-tail) was
considered significant.
■ RESULTS
Preparation and Characterization of Doxorubicin-
Loaded Nanoparticles with Various Surface Modifica-
tions. The following DOX-incorporated nanoparticles were
prepared: DOX-NPs (DOX-incorporated PLGA nanoparticles
without surface modification), DOX-M-NPs (DOX-NPs that
were surface-modified with mannose but not PEGylated),
DOX-AS-NPs (DOX-NPs that were PEGylated with acid-
sensitive sheddable PEG, but not surface-modified with
mannose), DOX-AS-M-NPs (DOX-NPs that were surface-
modified with mannose and PEGylated with acid-sensitive
sheddable PEG), and DOX-AI-M-NPs (DOX-NPs that were
surface-modified with mannose and PEGylated with the acid-
insensitive PEG2000-amide-C18) (Figure 1A). All DOX-loaded
nanoparticles were around 130−150 nm in diameter, with a
narrow size distribution (see polydispersity indices) (Figure
1A). The zeta potentials of DOX-loaded nanoparticles were
−24 to −35 mV (Figure 1A). The entrapment efficiency of
DOX was 60−70% (Figure 1A). The nanoparticles were
spherical (e.g., DOX-AS-M-NPs, Figure 1B). The release of the
DOX from the nanoparticles was biphasic; a typical burst
release phase was followed by a slower release phase (Figure
1C). The cytotoxicity of the DOX-loaded nanoparticles was
tested in B16-F10 mouse melanoma cells and in J774A.1 mouse
macrophage cells. In B16-F10 cells, the IC50 values of all DOX-
loaded nanoparticles were not different from one another, but
they were significantly higher than that of free DOX (Figure
1D). In J774A.1 cells, except the DOX-M-NPs, the IC50 values
of all other DOX-loaded nanoparticles were not different from
that of free DOX (Figure 1D). However, after the DOX-AS-M-
NPs were preincubated in a pH 6.8 buffer for 6 h to facilitate
the shedding of the PEG chains before they were added into
cells, their IC50 value in J774A.1 cells was significantly
Figure 2. Uptake of DOX-incorporated nanoparticles by J774A.1 murine macrophages in culture. (A) Uptake of different DOX-nanoparticles (red)
that were preincubated or not, at pH 6.8 for 6 h. Cells were incubated with DOX-nanoparticles for 20 min. (B) Intracellular location of DOX (red)
or DOX-AS-M-NPs (green) after incubated with J774A.1 cells for 20 min, 30 min, or 1 h. Cell nuclei were stained with Hoechst (blue).
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decreased (by more than 50%) (Figure 1D). The cytotoxicity
of DOX-AS-M-NPs after preincubation at pH 6.8 was evaluated
only in J774A.1 cells because there is evidence that the murine
macrophages cells express mannose receptor.34,39
In Vitro Cellular Uptake of DOX-Loaded Nanoparticles
by J774A.1 Macrophages. To verify the surface modification
of DOX-nanoparticles (i.e., PEGylation and/or mannose-
modification), the uptakes of various DOX-loaded nano-
particles, DOX-NPs, DOX-M-NPs, DOX-AI-M-NPs, and
DOX-AS-M-NPs, by J774A.1 mouse macrophages were
evaluated microscopically after the nanoparticles were
preincubated in PBS (pH 6.8) for 6 h. A minimum 6 h of
incubation is needed for the shedding of 50% of the PEG
chains.34 Without the 6 h preincubation at pH 6.8, only the
uptake of the DOX-M-NPs was extensive (Figure 2A).
However, after 6 h of preincubation, the cellular uptake of
the DOX-AS-M-NPs, but not the DOX-AI-M-NPs, was
significantly increased to a level similar to that of the DOX-
M-NPs (Figure 2A).
The red fluorescent signals in Figure 2A were from the DOX
and were an indirect indication of the uptake of the DOX-
nanoparticles. A further step was taken by labeling the AS-M-
NPs with fluorescein (FITC was chemically conjugated to
PLGA molecules) to directly observe the cellular uptake of the
nanoparticles. As shown in Figure 2B, DOX (red fluorescence
signal) was observed in the cytoplasm of cells in 20 min, and
within 1 h after incubation, it was in both cytoplasm and cell
nuclei (i.e., overlap of red and blue signals). FITC-labeled
nanoparticles (green signals) were observed in the cytoplasm in
20 min as well, and the fluorescence intensity in the cytoplasm
was increased as the incubation time was increased (to 1 h)
(Figure 2B). However, the green fluorescence signals remained
in the cytoplasm, not detectable in the cell nuclei (Figure 2B).
The DOX that accumulated in the cell nuclei may be released
from the DOX-AS-M-NPs before and/or after the cellular
internalization of the nanoparticles.
Biodistribution of Doxorubicin-Loaded Nanoparticles
with Various Surface-Modifications in Tumor-Bearing
Mice. To evaluate the extent to which the AS-M-NPs can
deliver DOX into tumors, while minimizing its accumulation in
MPS organs (e.g., liver and spleen), the distribution of DOX in
tumors, blood, and major organs in C57BL/6 mice with pre-
established subcutaneous (s.c.) B16-F10 tumors was analyzed
after free DOX or DOX-nanoparticles were i.v. injected into the
mice. As shown in Figure 3A (and Figure S1, Supporting
Information), in mice that were injected with DOX-NPs or
DOX-M-NPs, especially the DOX-M-NPs, significant DOX
accumulation was observed in mouse liver, spleen, lung, and
kidneys, but not in tumors, 6 h after the injection. In mice that
were injected with the DOX-AI-M-NPs, DOX distribution in
the liver, spleen, lung, and kidneys of the mice was reduced, but
increased in tumor (Figures 3A and S1, Supporting
Information). In mice that were injected with the DOX-AS-
M-NPs, DOX distribution in tumor was further increased, as
compared to in mice that were injected with DOX-AI-M-NPs
(Figures 3A and S1, Supporting Information). Shown in Figure
3B are the fluorescence intensities of DOX in the mouse blood
6 h after mice were injected with free DOX or various DOX-
nanoparticles. The fluorescence intensity was higher in mice
that were injected with DOX-AI-M-NPs or DOX-AS-M-NPs
Figure 3. Biodistribution of DOX in B16-F10 tumor-bearing mice. Representative ex vivo fluorescence images of B16-F10 tumors and other major
organs (A) and mean fluorescent intensity of DOX in mouse blood samples (B), 6 h after mice were i.v. injected with PBS, DOX, DOX-NPs, DOX-
M-NPs, DOX-AI-M-NPs, or DOX-AS-M-NPs (a−cp < 0.05). (C) Representative ex vivo images of B16-F10 tumors and other major organs 6, 12, 24,
or 48 h after mice were i.v. injected with DOX-AS-M-NPs. (D) Mean fluorescent intensity of DOX in tumors, organs, and blood at various time
points after mice were i.v. injected with DOX-AS-M-NPs. (E) Representative ex vivo images of B16-F10 tumors and other major organs 6 h after
mice were injected with DOX-AS-M-NPs or DOX-AS-NPs. Imaging was repeated in at least 3 mice, with similar trends (T = tumor, K = kidneys, H
= heart, Lr = liver, S = spleen, and Ln = lung).
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and relatively lower in mice that were injected with the DOX-
NPs or DOX-M-NPs (Figure 3B). Shown in Figures 3C−D
(and Figure S2, Supporting Information) are the biodistribu-
tion of the DOX-AS-M-NPs in s.c. B16-F10 tumor-bearing
mice 6, 12, 24, and 48 h after i.v. injection. The fluorescence
intensity of DOX-AS-M-NPs peaked in tumors about 24 h after
i.v. injection, whereas the contents DOX-AS-M-NPs in blood
and other organs slowly decreased as a function of time
(Figures 3C,D and S2, Supporting Information).
In order to verify the function of the mannose-modification
on the biodistribution of the nanoparticles, the biodistribution
of the DOX-AS-M-NPs in B16-F10 tumor-bearing mice was
compared with that of the DOX-AS-NPs. The accumulation of
DOX in tumors in mice that were i.v. injected with the DOX-
AS-NPs was significantly lower than in mice that were i.v.
injected with the DOX-AS-M-NPs (Figures 3E and S3,
Supporting Information).
Finally, to confirm that the DOX-AS-M-NPs are effective in
delivering DOX into tumors other than the B16-F10 tumors,
athymic nude mice with s.c. injected BxPC-3 human pancreatic
tumor cells and C57BL/6 mice with s.c. injected TC-1 mouse
lung cancer cells were used. As shown in Figure 4, DOX-AS-M-
NPs significantly increased the delivery of DOX in the BxPC-3
tumors (Figure 4A) and TC-1 tumors (Figure 4B), as
compared to free DOX.
Effect of the Depletion of TAMs on the Biodistribu-
tion of the DOX-AS-M-NPs in Tumor-Bearing Mice. To
understand the role of TAMs in the AS-M-NPs’ ability to target
DOX into tumors, B16-F10 tumor-bearing mice were treated
with zoledronic acid to reduce the macrophage population,
including TAMs. Immunohistochemical staining confirmed the
reduction of CD206+ staining (an M2 macrophage marker) in
tumors in mice that were treated with zoledronic acid (Figure
5A). The accumulation of DOX-AS-M-NPs in tumors in mice
that were treated with zoledronic acid was significantly
decreased, as compared to that in mice that were not treated
with zoledronic acid (Figures 5B and S4, Supporting
Information).
Uptake of DOX-AS-M-NPs by TAMs in B16-F10
Tumor-Bearing Mice. To test whether DOX-AS-M-NPs
increase the uptake of DOX by TAMs, B16-F10 tumor-bearing
mice were i.v. injected with free DOX or various DOX-
Figure 4. (A) Relative fluorescence intensities of DOX in tumors and major organs of athymic nude mice 6 h after they were i.v. injected with DOX-
AS-M-NPs or free DOX. (B) Relative fluorescence intensities of DOX in tumors and major organs of C57BL/6 mice 12 h after they were i.v.
injected with DOX-AS-M-NPs or free DOX. Imaging was repeated in 2−3 mice/group (K = kidneys, H = heart, and S = spleen) (*p < 0.05, DOX-
AS-M-NPs, vs DOX or PBS in tumors).
Figure 5. (A) Representative images of B16-F10 tumors stained with RM0029-11H3. Tumor-bearing mice were treated, or not, with zoledronic acid
(ZA). (B) Representative ex vivo images of B16-F10 tumors and other major organs 6 h after mice were injected with DOX-AS-M-NPs. Prior to the
injection of DOX-AS-M-NPs, one group of mice was treated with ZA (T = tumor, K = kidneys, H = heart, Lr = liver, S = spleen, and Ln = lung).
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nanoparticles, and the percent of CD206+ cells that contained
DOX (i.e., DOX+/CD206+%) was measured using flow
cytometry 6 h after injection. As shown in Figure 6A,B, the
percent of DOX+/CD206+ cells in tumors in mice that were i.v.
injected with DOX-AS-M-NPs was significantly higher than in
mice that were injected with free DOX, DOX-AI-M-NPs, or
DOX-AS-NPs. In fact, it was 2−3-fold higher in tumors in mice
that were injected with the DOX-AS-M-NPs than with other
nanoparticles or free DOX (Figure 6B).
In Vivo Antitumor Activity of the DOX-AS-M-NPs.
Because the DOX-AS-M-NPs were shown to be more effective
than other nanoparticles in delivering DOX into tumors, while
minimizing the accumulation of DOX in MPS organs such as
liver, the antitumor activity of DOX-AS-M-NPs was evaluated
in B16-F10 tumor-bearing mice and compared to that of free
DOX. B16-F10 tumors in mice that were i.v. injected with the
DOX-AS-M-NPs grew significantly slower than in mice that
were injected with free DOX at an identical DOX dose (Figure
7A). At the end of the study (i.e., 16 days after tumor cell
injection), the mean weight of tumors in mice that were treated
with DOX-AS-M-NPs was about 50% of that in mice that were
treated with free DOX, less than 20% of that in mice left
untreated (Figure 7B). Shown in Figure 7C are digital images
of tumors at the end of the study, and the mean body weights
of the mice during the treatment period are in Figure 7D.
Tumors in mice that were injected with sterile PBS (i.e.,
negative control) showed large cell nuclei and small
intercellular spaces, with necrosis and hemorrhage rarely
observable (H&E), while CD31+ (an angiogenesis maker)
and BrdU+ staining (a cell proliferation marker) were extensive
(Figure 7E). Tumors in mice that were treated with free DOX
had some necrotic areas and small hemorrhagic regions, and
CD31+ and BrdU+ staining remained extensive (Figure 7E). In
contrast, tumors in mice that were treated with DOX-AS-M-
Figure 6. Uptake of DOX by CD206+ cells in B16-F10 tumors 6 h after tumor-bearing mice were i.v. injected with free DOX or various DOX-
nanoparticles. (A) Representative flow cytometric graphs of single tumor cell suspensions after stained with FITC-labeled anti-CD206. (B) The
percentage of CD206+ cells in B16-F10 tumors that took up DOX (i.e., DOX+/CD206+%). Data are mean ± SEM from at least 3 mice (a−cp < 0.05).
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NPs showed numerous necrotic and hemorrhagic areas, with
decreased CD31+ staining and BrdU+ staining (Figure 7E).
Effect of Treatment with DOX-AS-M-NPs on TAMs and
on Macrophages in Liver and Spleen. To evaluate the
effect of the DOX-AS-M-NPs on TAMs and macrophages in
MPS, the tumor, liver, and spleen tissues from B16-F10 tumor-
bearing mice that were treated with DOX-AS-M-NPs were
stained with anti-CD206 (an M2 macrophage marker) or
RM0029-11H3 (a pan-macrophage marker). Mice were treated
with DOX-AS-M-NPs or free DOX at 6 and 12 days after
tumor cell injection, and tissues were collected 4 days after the
second treatment. As shown in Figure 8A, the extent of
CD206+ staining was significantly lower in tumors in mice that
were treated with DOX-AS-M-NPs than in mice that were
treated with free DOX or left untreated. However, there was no
apparent difference in the extents of RM0029-11H3+ staining in
the liver and spleen in mice that were treated with DOX-AS-M-
NPs or free DOX (Figure 8B).
■ DISCUSSION
Traditionally, active tumor-targeting is focused on exploiting
receptors and proteins that are overexpressed by tumor cells or
Figure 7. in vivo antitumor activity of DOX-AS-M-NPs. (A) Growth curves of B16-F10 tumors in C57BL/6 mice that were treated with DOX-AS-
M-NPs (●) or free DOX (▲). B16-F10 tumor cells were injected in mice on day 0. Arrows indicate days on which mice were treated (*p < 0.05,
DOX vs DOX-AS-M-NPs). Mean weight (B) and digital photographs (C) of tumors on day 16 (in panel B, a,bp < 0.05). (D) Mouse body weight.
(E) Representative micrographs of tumors stained with H&E, anti-CD31 antibody, or anti-BrdU antibody (anecrotic areas, bhemorrhagic regions,
and cblood vessels). For H&E and anti-CD31 staining, bar = 100 μm; for anti-BrdU staining, bar = 50 μm. In panels A, B, and D, data are mean ±
SEM (n = 8).
Figure 8. Representative micrographs of (A) tumor tissues stained with anti-CD206 antibody (bar = 50 μm) and (B) liver and spleen tissues stained
with RM0029-11H3 (bar = 100 μm).
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molecules that are overexpressed in tumor neovasculature.40,41
Recently, there is increasing interest in exploring other cellular
or noncellular components in tumor tissues, such as immune
cells, fibroblasts, and extracellular matrix materials, for active
tumor targeting.42−44 TAMs are critical in tumors.8 In fact,
there have been some efforts in utilizing TAMs as a target for
tumor imaging.45,46 Targeting of TAMs instead of tumor cells
has many advantages. Altering the tumor microenvironment
that is involved in tumor angiogenesis and progression could
markedly decrease metastasis, gaining better response to tumor
resistance.47,48 In addition, since TAMs exist mainly in the
stroma of many tumors,6,8 targeting of TAMs could be an
effective antitumor strategy for a wide variety of tumors. Our
data indicated that acid-sensitive sheddable PEGylation and
mannose-modification of PLGA nanoparticles could increase
the distribution of the PLGA nanoparticles in tumor tissues via
interaction with TAMs while decreasing their accumulation in
MPS organs such as liver.
As shown in Figure 3A, upon i.v. injection, free DOX hardly
accumulated in tumors and major organs such as liver, spleen,
heart, lung, and kidneys. The un-PEGylated DOX-NPs mainly
accumulated in MPS organs such as liver, likely due to
opsonization.49 DOX-M-NPs were un-PEGylated, but surface-
modified with mannose, and their accumulation in mouse liver,
lung, and kidneys were further increased, as compared to DOX-
NPs, likely because of the presence of MR-expressing
macrophages in those organs as well.50,51 Both DOX-AS-M-
NPs and DOX-AI-M-NPs are PEGylated, and as expected, their
distributions in major organs such as liver, lung, and kidneys
were significantly decreased, but increased in tumor tissues
(Figure 3A), and data in Figure 3B indicate that PEGylation
increased the blood circulation time of the nanoparticles.
Importantly, compared to DOX-AI-M-NPs, the distribution of
DOX-AS-M-NPs in tumor was significantly higher, demonstrat-
ing the importance of acid-sensitive sheddable PEGylation in
increasing the delivery of the nanoparticles into tumors. In
order to understand the significance of surface-modification
with mannose on the nanoparticles’ ability to target tumors, the
biodistribution of DOX-AS-M-NPs and DOX-AS-NPs were
compared, and data in Figure 3E showed that the tumor
accumulation of DOX-AS-M-NPs was significantly higher than
that of DOX-AS-NPs, confirming that both acid-sensitive
sheddable PEGylation and surface-modified with mannose are
required for successful targeting of the DOX-NPs into tumors.
Data in Figure 4 showed that upon i.v. injection DOX-AS-M-
NPs increased the delivery of DOX into s.c. BxPC-3 tumors in
athymic nude mice and s.c. TC-1 tumors in C57BL/6 mice.
The observed relatively higher accumulation in spleen was
likely related to the relatively higher background fluorescence
signal in the spleen (especially in the TC-1 tumor bearing mice
(Figure 4B)), as compared to in other organs tested. A similar
trend was also observed when tested in male nude mice with
orthotopic Panc-1 human pancreatic tumors and in female
nude mice with orthotopic MDA-MB-231 human breast
tumors (data not shown). Therefore, the AS-M-NPs’ ability
to increase the biodistribution of molecules carried by them
into tumors is not limited to the B16-F10 tumors. TAMs are
critical for the AS-M-NPs to target tumors, and thus, the
distribution of AS-M-NPs in different tumors will likely be
affected by the population of TAMs in the tumors. B16-F10
tumors in C57BL/6 mice reportedly contain only 6−8% of
TAMs.52 Therefore, the AS-M-NPs will likely be more effective
in targeting tumors that contain a higher population of TAMs.
Zoledronic acid belongs to a group of bisphosphonates,
which are often used to reduce macrophage population in
mouse models.37 Data in Figure 5B showed that the
distribution of DOX-AS-M-NPs in tumors in mice that were
treated with zoledronic acid was significantly reduced, as
compared to in similar tumor-bearing mice that were not
treated with zoledronic acid, demonstrating that TAMs are
required for the AS-M-NPs to successfully improve the
distribution of DOX into tumors. In fact, DOX-AS-M-NPs
increased the uptake of DOX by TAMs in B16-F10 tumor-
bearing mice by 2−3-fold, as compared to DOX-AI-M-NPs or
DOX-AS-NPs (Figure 6), further indicating that the interaction
between the mannose on the surface of the DOX-AS-M-NPs
and TAMs after acid-sensitive shedding of the PEG chains from
the nanoparticles in tumor tissues is critical for the enhanced
delivery of DOX into tumors.
Data in Figure 7 showed that DOX-AS-M-NPs are
significantly more effective than free DOX in controlling
tumor growth. In addition, the DOX-AS-M-NPs were also
more effective than free DOX in suppressing angiogenesis
(CD31+ staining) and cell proliferation (BrdU+ staining) in
tumor tissues (Figure 7E). The stronger antitumor activity of
the DOX-AS-M-NPs is likely in part due to the nanoparticle’s
ability to increase the delivery of DOX into tumors (Figure
3A). However, it remains unknown to what extent the stronger
antitumor activity of the DOX-AS-M-NPs can be attributed to
their ability to reduce the TAM population in tumors (Figure
8A). In vitro cytotoxicity data showed that DOX-AS-M-NPs
were cytotoxic not only to B16-F10 tumor cells, but also to the
J774A.1 macrophages, and shedding of the PEG chains on the
DOX-AS-M-NPs significantly increased the nanoparticle’s
cytotoxicity to J774A.1 cells (Figure 1D). In addition, data in
Figure 6 showed that, in B16-F10 tumor-bearing mice, i.v.
injection of DOX-AS-M-NPs almost doubled the percentage of
TAMs that took up DOX, as compared to i.v. injection of free
DOX. Therefore, the strong antitumor activity of the DOX-AS-
M-MPs is likely related to their ability to reduce TAM
population in tumors. It is possible that B16-F10 tumors with a
reduced population of TAMs are smaller than the same B16-
F10 tumors with a normal population of TAMs. In addition,
since TAMs promote tumor cell proliferation and induce
immune suppression, a reduction of TAM population in tumors
may also have contributed to the slower tumor growth in mice
that were treated with DOX-AS-M-NPs. Of course, although
DOX-AS-M-NPs increased the delivery of DOX into TAMs
(Figure 6), it is unlikely that all the DOX-AS-M-NPs that
reached the tumor were taken up by TAMs. Some DOX-AS-M-
NPs that were delivered to tumor tissues were likely taken up
by B16-F10 tumor cells. In addition, some DOX that was
released from the DOX-AS-M-NPs, before or after the
nanoparticles reached tumors, may also have been taken up
by tumor cells. Therefore, the mechanism underlying the strong
antitumor activity of the DOX-AS-M-NPs is expected to be
multifactorial. For example, the DOX-AS-M-NPs were also
more effective than DOX alone in inhibiting angiogenesis and
cell proliferation in tumors (Figure 7E). It was noted that
extensive necrosis was present in tumors in mice treated with
DOX-AS-M-NPs (Figure 7E). Low concentrations of DOX
induce necrosis, instead of apoptosis.53 It is possible that the
DOX that was slowly released from the DOX-AS-M-NPs
maintained a low concentration of DOX in the tumor tissues
and caused the significant necrosis.
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Shown in Figure 8 are the micrographs of tumor, liver, and
spleen tissues of B16-F10 tumor-bearing mice after the tissues
were stained with anti-CD206 (an M2 macrophage marker) or
RM0029-11H3 (a pan-macrophage marker). Compared to the
tumor tissues from mice treated with free DOX or left
untreated, the extent of CD206+ staining was significantly
decreased in tumors in mice that were treated with DOX-AS-
M-NPs (Figure 8A), demonstrating DOX-AS-M-NPs’ ability to
reduce TAM population in tumor tissues. Importantly, the
extents of RM0029-11H3-positive staining in both liver and
spleen of mice that were treated with DOX-AS-M-NPs appear
not different from that in mice treated with free DOX or left
untreated (Figure 8B), indicating that the DOX-AS-M-NPs did
not significantly affect the total macrophage population in MPS
organs such as liver and spleen.
Many compounds including the bisphosphonate zoledronic
acid can be used to deplete TAMs.54 However, zoledronic acid
also significantly affects macrophages that do not reside in
tumors. The AS-M-NPs are advantageous because they can
target tumors and TAMs but have only minimum effects on
macrophages that are not tumor-associated. Of course, since
macrophages are white blood cells differentiated from
monocytes, arising from progenitor cells in the bone marrow,55
there is the possibility that 4 days after the second treatment of
the B16-F10 tumor-bearing mice with DOX-AS-M-NPs any
major effects that the DOX-AS-M-NPs may have had on
macrophages in MPS organs were restored, whereas the TAM
population in tumors may take a longer time to replenish. More
experiments will need to be carried out to study the effect of
the DOX-AS-M-NPs on the dynamics of macrophages in tumor
and nontumor tissues in the future. Nonetheless, when fully
developed, the TAM-targeting nanoparticle platform can
potentially be applied to deliver cytotoxic agents or macro-
phage-modulating agents into tumors to decouple the
interaction between TAMs and tumor cells, making the
tumor microenvironment less favorable for tumor growth, but
more favorable for chemotherapy.
■ CONCLUSIONS
We demonstrated that surface-modification of PLGA nano-
particles with acid-sensitive sheddable PEG molecules and
mannose as a ligand of MR, which is overexpressed on TAMs,
allows the nanoparticles to effectively target DOX into tumors.
The targeting is dependent on the presence of sufficient TAMs
in tumors. Compared to free DOX, DOX carried by the acid-
sensitive sheddable PEGylated, mannose-modified PLGA
nanoparticles more effectively inhibited tumor growth, reduced
TAM population in tumors, but showed no or only minimum
effect on the macrophage population in MPS.
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